These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38665106)

  • 1. [Novel immunomodulatory therapies in myasthenia gravis].
    Sukockiené E; Théaudin M; Loser V; Staedler K; Lalive PH; Lascano AM
    Rev Med Suisse; 2024 Apr; 20(871):848-851. PubMed ID: 38665106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status.
    Beecher G; Putko BN; Wagner AN; Siddiqi ZA
    Drugs; 2019 Mar; 79(4):353-364. PubMed ID: 30762205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myasthenia gravis: emerging new therapy options.
    Sieb JP
    Curr Opin Pharmacol; 2005 Jun; 5(3):303-7. PubMed ID: 15907918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
    Howard JF; Bril V; Burns TM; Mantegazza R; Bilinska M; Szczudlik A; Beydoun S; Garrido FJRR; Piehl F; Rottoli M; Van Damme P; Vu T; Evoli A; Freimer M; Mozaffar T; Ward ES; Dreier T; Ulrichts P; Verschueren K; Guglietta A; de Haard H; Leupin N; Verschuuren JJGM;
    Neurology; 2019 Jun; 92(23):e2661-e2673. PubMed ID: 31118245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab in myasthenia gravis: a "to be or not to be" inhibitor of T cell function.
    Marino M; Bartoccioni E; Alboini PE; Evoli A
    Ann N Y Acad Sci; 2018 Feb; 1413(1):41-48. PubMed ID: 29369382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use and monitoring of low dose rituximab in myasthenia gravis.
    Blum S; Gillis D; Brown H; Boyle R; Henderson R; Heyworth-Smith D; Hogan P; Kubler P; Lander C; Limberg N; Pillans P; Prain K; Staples C; Walsh M; McCombe P; Wong R
    J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):659-63. PubMed ID: 21071753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals.
    Menon D; Bril V
    Drugs; 2022 Jun; 82(8):865-887. PubMed ID: 35639288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies.
    Dalakas MC
    Curr Opin Neurol; 2020 Oct; 33(5):545-552. PubMed ID: 32833750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose rituximab treatment for new-onset generalized myasthenia gravis.
    Li H; Huang Z; Jia D; Xue H; Pan J; Zhang M; Shi K; Shi FD; Zhang C
    J Neuroimmunol; 2021 May; 354():577528. PubMed ID: 33662696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab in Myasthenia Gravis - Where do we stand?
    Siddiqi ZA; Khan W; Hussain FS
    Expert Opin Biol Ther; 2021 Aug; 21(8):1013-1023. PubMed ID: 33566716
    [No Abstract]   [Full Text] [Related]  

  • 11. Promising therapies for the treatment of myasthenia gravis.
    Uysal SP; Morren JA
    Expert Opin Pharmacother; 2024 Mar; 25(4):395-408. PubMed ID: 38523508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoactive treatment for myasthenia gravis; a Chinese experience.
    Gilhus NE
    CNS Neurosci Ther; 2020 Dec; 26(12):1203-1204. PubMed ID: 33107208
    [No Abstract]   [Full Text] [Related]  

  • 13. Memory B cell resurgence requires repeated rituximab in myasthenia gravis.
    Muto K; Matsui N; Unai Y; Sakai W; Haji S; Udaka K; Miki H; Furukawa T; Abe M; Kaji R
    Neuromuscul Disord; 2017 Oct; 27(10):918-922. PubMed ID: 28694074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab for myasthenia gravis: three case reports and review of the literature.
    Stieglbauer K; Topakian R; Schäffer V; Aichner FT
    J Neurol Sci; 2009 May; 280(1-2):120-2. PubMed ID: 19272616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.
    Iorio R; Damato V; Alboini PE; Evoli A
    J Neurol; 2015 May; 262(5):1115-9. PubMed ID: 25308632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy in myasthenia gravis in the era of biologics.
    Dalakas MC
    Nat Rev Neurol; 2019 Feb; 15(2):113-124. PubMed ID: 30573759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myasthenia gravis: from autoantibodies to therapy.
    Mantegazza R; Bernasconi P; Cavalcante P
    Curr Opin Neurol; 2018 Oct; 31(5):517-525. PubMed ID: 30156572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting autoimmune mechanisms by precision medicine in Myasthenia Gravis.
    Cavalcante P; Mantegazza R; Antozzi C
    Front Immunol; 2024; 15():1404191. PubMed ID: 38903526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myasthenia gravis with antibodies to MuSK: an update.
    Evoli A; Alboini PE; Damato V; Iorio R; Provenzano C; Bartoccioni E; Marino M
    Ann N Y Acad Sci; 2018 Jan; 1412(1):82-89. PubMed ID: 29266255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab treatment of myasthenia gravis: A systematic review.
    Tandan R; Hehir MK; Waheed W; Howard DB
    Muscle Nerve; 2017 Aug; 56(2):185-196. PubMed ID: 28164324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.